The role of the apelinergic and vasopressinergic systems in the regulation of the cardiovascular system and the pathogenesis of cardiovascular disease

Kardiologia Polska

Volumn 72, Issue 2, 2014, Pages 122-125

  Czarzasta, Katarzyna ^a   Cudnoch Jedrzejewska, Agnieszka ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APELIN; ARGIPRESSIN; COPEPTIN; CREATINE KINASE; LACTATE DEHYDROGENASE; MALONALDEHYDE; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA; VASOPRESSIN RECEPTOR; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR; SIGNAL PEPTIDE; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

ABDOMINAL FAT; ADIPOSE TISSUE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM REGULATION; FOOD INTAKE; HEART BLOOD VESSEL; HUMAN; HYPOTHALAMUS; INCIDENCE; LIPID DIET; NONHUMAN; OBESITY; PATHOGENESIS; REGULATORY MECHANISM; REVIEW; SOLITARY TRACT NUCLEUS; STRESS; SUPRAOPTIC NUCLEUS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DRUG EFFECTS; PATHOPHYSIOLOGY;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 84895191791     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: 10.5603/KP.2014.0028     Document Type: Review

References (48)

1. Szczepanska-Sadowska E, Cudnoch-Jedrzejewska A, Ufnal M, Zera T. Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases. J Physiol Pharmacol, 2010; 61: 509-521.
2. Cudnoch-Jedrzejewska A, Gomolka R, Czarzasta K et al. Reduced central pressor action of apelin in Sprague Dawley rats maintained on high fat diet or exposed to chronic stressing. J Physiol Pharmacol, 2011; 62: 89.
3. Cudnoch-Jedrzejewska A, Czarzasta K, Gomolka R, Szczepanska Sadowska E. The role of apelin in pathogenesis of cardiovascular diseases and metabolic disorders. Kardiol Pol, 2011; 69: 89-93.
4. Pisarenko OI, Serebryakova LI, Studneva IM et al. Effects of structural analogues of apelin-12 in acute myocardial infarction in rats. J Pharmacol Pharmacother, 2013; 4: 198-203.
5. Wang W, McKinnie SM, Patel VB et al. Loss of Apelin Exacerbates Myocardial Infarction Adverse Remodeling and Ischemia-reperfusion Injury: therapeutic Potential of Synthetic Apelin Analogues. J Am Heart Assoc, 2013; 2: e000249.
6. Tatemoto K, Hosoya M, Habata H et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun, 1998; 251: 471-476.
7. Falcão-Pires I, Leite-Moreira AF. Apelin: a novel neurohumoral modulator of the cardiovascular system. Pathophysiologic importance and potential use as a therapeutic target. Rev Port Cardiol, 2005; 24: 1263-1276.
8. Jia ZQ, Hou L, Leger A et al. Cardiovascular effects of a PEGylated apelin. Peptides, 2012; 38: 181-188.
9. Japp AG, Newby DE. The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol, 2008; 75: 1882-1892.
10. Zhang J, Ren CX, Qi YF et al. Exercise training promotes expression of apelin and APJ of cardiovascular tissues in spontaneously hypertensive rats. Life Sci, 2006; 79: 1153-1159.
11. Zhang CR, Xia CM, Jiang MY et al. Repeated electroacupuncture attenuating of apelin expression and function in the rostral ventrolateral medulla in stress-induced hypertensive rats. Brain Res Bull, 2013; 97: 53-62.
12. Sonmez A, Celebi G, Erdem G et al. Plasma apelin and ADMA levels in patients with essential hypertension. Clin Exp Hypertens, 2010; 32: 179-183.
13. Pchejetski D, Foussal C, Alfarano C et al. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J, 2012; 33: 2360-2369.
14. Chen MM, Ashley EA, Deng DX et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation, 2003; 108: 1432-1439.
15. Miettinen KH, Magga J, Vuolteenaho O et al. Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. Regul Pept, 2007; 140:178-184.
16. Azizi Y, Faghihi M, Imani A et al. Post-infarct treatment with [Pyr1]-apelin-13 reduces myocardial damage through reduction of oxidative injury and nitric oxide enhancement in the rat model of myocardial infarction. Peptides, 2013; 46: 76-82.
17. Tempel D, de Boer M, van Deel ED et al. Apelin enhances cardiac neovascularization after myocardial infarction by recruiting aplnr+ circulating cells. Circ Res, 2012; 111: 585-598.
18. Sawane M, Kajiya K, Kidoya H et al. Apelin inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity. Diabetes, 2013; 62: 1970-1980.
19. Lv SY, Yang YJ, Qin YJ et al. Central apelin-13 inhibits food intake via the CRF receptor in mice. Peptides, 2012; 33: 132-138.
20. Krist J, Wieder K, Klöting N et al. Effects of weight loss and exercise on apelin serum concentrations and adipose tissue expression in human obesity. Obes Facts, 2013; 6: 57-69.
21. Cavallo MG, Sentinelli F, Barchetta I et al. Altered glucose homeostasis is associated with increased serum apelin levels in type 2 diabetes mellitus. PLoS One, 2012; 7: e51236.
22. Castan-Laurell I, Dray C, Attané C et al. Apelin, diabetes, and obesity. Endocrine, 2011; 40: 1-9.
23. Ceylan-Isik AF, Kandadi MR, Xu X et al. Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction. J Mol Cell Cardiol, 2013. pii: S0022-2828(13)00224-1.
24. Czarzasta K, Cudnoch-Jȩdrzejewska A, Gomółka R et al. Wpływ diety wysokotłuszczowej na ośrodkowa̧ regulacjȩ ciśnienia tȩtniczego u szczurów zdrowych i szczurów z pozawałowa̧ niewydolnościa̧ serca. XVII Sympozjum Sekcji Kardiologii Eksperymentalnej Polskiego Towarzystwa Kardiologicznego oraz Komitetu Nauk Fizjologicznych i Farmakologicznych Polskiej Akademii Nauk 2012; 6.
25. O'Carroll AM, Don AL, Lolait SJ. APJ receptor mRNA expression in the rat hypothalamic paraventricular nucleus: regulation by stress and glucocorticoids. J. Neuroendocrinol, 2003; 15: 1095-1101.
26. Newson MJ, Pope GR, Roberts EM et al. Stress-dependent and gender-specific neuroregulatory roles of the apelin receptor in the hypothalamic-pituitary-adrenal axis response to acute stress. J Endocrinol, 2013; 216: 99-109.
27. Szinnai G, Morgenthaler NG, Berneis K et al. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab, 2007; 92: 3973-3978.
28. Ostrowski NL, Lolait SJ, Bradley DJ et al. Distribution of V1a and V2 vasopressin receptor messenger ribonucleic acids in rat liver, kidney, pituitary and brain. Endocrinology, 1992; 131: 533-535.
29. Hallbeck M, Hermanson O, Blomqvist A. Distribution of preprovasopressin mRNA in the rat central nervous system. J Comp Neurol, 1999; 411: 181-200.
30. Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E, Dobruch J et al. Brain vasopressin V(1) receptors contribute to enhanced cardiovascular responses to acute stress in chronically stressed rats and rats with myocardial infarction. Am J Physiol Regul Integr Comp Physiol, 2010; 298: R672-R680.
31. Jackiewicz E, Szczepanska-Sadowska E, Dobruch J. Altered expression of angiotensin AT1a and vasopressin V1a receptors and nitric oxide synthase mRNA in the brain of rats with renovascular hypertension. J Physiol Pharmacol, 2004; 55: 725-737.
32. Nazari A, Sadr SS, Faghihi M et al. The cardioprotective effect of different doses of vasopressin (AVP) against ischemia-reperfusion injuries in the anesthetized rat heart. Peptides, 2011; 32: 2459-2466.
33. Lanfear DE, Sabbah HN, Goldsmith SR et al. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail, 2013; 6: 47-52.
34. Morgenthaler NG. Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail, 2010; 16 (suppl): S37-S44.
35. Neuhold S, Huelsmann M, Strunk G et al. Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy. Clin Chem, 2010; 56: 121-126.
36. Neuhold S, Huelsmann M, Strunk G et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol, 2008; 52: 266-272.
37. Kelly D, Squire IB, Khan SQ et al. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail, 2008; 14: 739-745.
38. Küchler S, Perwitz N, Schick RR et al. Arginine-vasopressin directly promotes a thermogenic and pro-inflammatory adipokine expression profile in brown adipocytes. Regul Pept, 2010; 164: 126-132.
39. Aoyagi T, Kusakawa S, Sanbe A et al. Enhanced effect of neuropeptide Y on food intake caused by blockade of the V(1A) vasopressin receptor. Eur J Pharmacol, 2009; 622: 32-36.
40. Nakamura K, Yamashita T, Fujiki H et al. Enhanced glucose tolerance in the Brattleboro rat. Biochem Biophys Res Commun, 2011; 405: 64-67.
41. Enhörning S, Leosdottir M, Wallström P et al. Relation between human vasopressin 1a gene variance, fat intake, and diabetes. Am J Clin Nutr, 2009; 89: 400-406.
42. Enhörning S, Bankir L, Bouby N et al. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort. Int J Obes (Lond), 2013; 37: 598-603.
43. Zhang L, Hernández VS, Liu B et al. Hypothalamic vasopressin system regulation by maternal separation: its impact on anxiety in rats. Neuroscience, 2012; 215: 135-148.
44. Jasnic N, Djordjevic J, Vujovic P et al. The effect of vasopressin 1b receptor (V1bR) blockade on HPA axis activity in rats exposed to acute heat stress. J Exp Biol, 2013; 216: 2302-2307.
45. Dobruch J, Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E. Enhanced involvement of brain vasopressin V1 receptors in cardiovascular responses to stress in rats with myocardial infarction. Stress, 2005; 8: 273-284.
46. De Mota N, Reaux-Lee Goazigo A, El Messari S et al. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions trough inhibition of vasopressin neuron activity and vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci USA, 2004; 101: 10464-10469.
47. Tobin VA, Bull PM, Arunachalam S et al. The effects of apelin on the electrical activity of hypothalamic magnocellular vasopressin and oxytocin neurons and somatodendritic peptide release. Endocrinology, 2008; 149: 6136-6145.
48. Blanchard A, Steichen O, De Mota N et al. An abnormal apelin/vasopressin balance may contribute to water retention in patients with the syndrome of inappropriate antidiuretic hormone (SIADH) and heart failure. J Clin Endocrinol Metab, 2013; 98: 2084-2089.